Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 12 Issue 5, November 2018

Volume 12 Issue 5

In this issue...

• Partnering in neuroscience: deals, companies and financing trends

• Identifying and attracting a biopharma partner

Cover image: Magnified view of brain neurons. Ivan Cholakov, Alamy Stock Photo.

Partnering in neuroscience

    Feature

  • News Feature |

    Early-stage developments are attracting investment and driving dealmaking within the challenging neuroscience field, particularly for pain and Alzheimer’s disease, as the industry aims to move past the many late-stage clinical failures in recent years.

    • Jamie Munro
    • Helen Dowden
  • Profiles

  • Advertisement Feature |

    With multiple products in advanced clinical stages, including oral calcitonin gene-related peptide receptor antagonists, glutamate modulators, and myeloperoxidase inhibitors, Biohaven is advancing collaborations on these programs and broadening its pipeline.

    • Biohaven Pharmaceuticals, Inc.
  • Advertisement Feature |

    The Cuban Center for Neurosciences (CNEURO), a core institute of the Cuban organization of Biotechnology and Pharmaceutical Industries, BioCubaFarma, has developed a portfolio of technologies and services to diagnose and treat brain disorders and promote mental health from infancy to old age.

    • BioCubaFarma
  • Advertisement Feature |

    Unlike standard analgesics, the company’s lead compound ricolinostat is a disease-modifying therapy that reverses nerve damage and reduces pain, numbness, and muscle weakness resulting from diabetes, chemotherapy, and Charcot–Marie–Tooth disease.

    • Regenacy Pharmaceuticals
  • Advertisement Feature |

    M3 Biotechnology is advancing a novel, potentially transformative approach for the treatment of Alzheimer’s disease and other neurodegenerative diseases. Unlike other products approved and in development, M3’s drug candidates hold the potential to reverse or halt the degenerative process.

    • M3 Biotechnology

Identifying and attracting a biopharma partner

    Feature

  • News Feature |

    Continuing our dealmaking series, we explore one of the initial stages—finding a suitable partner—and provide advice on attracting and selecting the right match for your company and products.

    • Biopharma Dealmakers
  • Profiles

  • Advertisement Feature |

    Cryoport’s experience in cold chain logistics is now facing its biggest challenge yet—keeping patients’ therapies safe from damage in the revolutionary new field of cell therapy.

    • Cryoport Systems Inc.
  • Advertisement Feature |

    Providing a vast range of custom biologic services, including plasmid DNA production, mRNA production and antibody development, Aldevron is helping companies worldwide lay the foundations for groundbreaking science and discoveries.

    • Aldevron
  • Advertisement Feature |

    The precision genetics medicine company Mediphage has developed an innovative DNA ministrings platform for safe, effective, and accessible ex vivo (cell) and in vivo (gene) therapies, including chimeric antigen receptor T-cells (CAR-Ts), CRISPR/Cas, and pluripotent stem-cell therapeutic applications.

    • Mediphage
  • Advertisement Feature |

    TAGCyx Biotechnologies uses its proprietary Xenoligo technology platform to generate novel DNA aptamers containing an artificial nucleotide that have high affinity and selectivity for target proteins. TAGCyx is building a pipeline of Xenoligo aptamers and aptamer–drug conjugates, and is looking for global pharmaceutical partners.

    • TAGCyx Biotechnologies Inc.

Search

Quick links